[Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance].
This paper reviews recent data on the pharmacovigilance of antiparkinsonian drugs and drugs inducing parkinsonian syndroms. Sudden sleep attacks were first described in 1999 with dopamine agonists. In fact, they can be induced by all the dopaminergic antiparkinsonian drugs. Favorising factors are duration of the disease, dose of dopaminergic drugs, daytime somnolence or dysautonomia. This adverse drug reaction can be serious leading, for example, to road accidents. Cardiac valvulopathies were more recently (end of 2002) described with pergolide. Thus, this dopamine agonist should now be prescribed as a last choice among dopamine agonists. Dopamine drugs (levodopa as well as dopamine agonists) can induce hypersexual behaviours or pathological gambling. Among the long list of drugs inducing parkinsonian syndroms, recent data suggest the involvement of serotoninergic antidepressants, valproic acid and trimetazidine. Finally, these data on pharmacovigilance allow to precise the physiological role of dopamine: beside its motor and psychic effects, dopamine is also involved in the sleep-arousal control. It is also an important mediator for pleasure, hedonic regulations and sexual behaviour. This review also underlines the major role of spontaneous reports to the pharmacovigilance systems to identify new adverse drug reactions.
Montastruc
Jean-Louis
JL
Laboratoire de Pharmacologie Médicale et Clinique, Unité de Pharmacoépidémiologie, UA 3696, IFR 126, Université Paul Sabatier, Faculté de Médecine, Toulouse, France. montastruc@cict.fr
Sommet
Agnès
A
Olivier
Pascale
P
Bagheri
Haleh
H
Gony
Mireille
M
Lapeyre-Mestre
Maryse
M
Brefel-Courbon
Christine
C
Ferreira
Joachim
J
Schmitt
Laurent
L
Senard
Jean-Michel
JM
Rascol
Olivier
O
D000063:Accidents, Traffic / Q000706:statistics & numerical data; D000978:Antiparkinson Agents / Q000009:adverse effects*; D018491:Dopamine Agonists / Q000009:adverse effects; D011307:Drug Prescriptions / Q000592:standards*; D005602:France; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D020734:Parkinsonian Disorders / Q000188:drug therapy*
D000978:Antiparkinson Agents; D018491:Dopamine Agonists